|
Carcinoma
|
0.010 |
PosttranslationalModification
|
group |
BEFREE |
An analysis of genes possibly regulated by miR-181a-2* was carried out and, amongst these, an inverse correlation of NAMPT with miR-181a-2* expression was observed, whereas, for TRAF1 and SALL1, additional regulation mechanisms involving CpG island methylation were observed. miR-181a-2* is associated with particular histological and molecular features of colorectal carcinomas within the serrated pathological pathway and might play a role in the immune responses of microsatellite instability carcinomas.
|
31784758 |
2019 |
|
Colorectal Carcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
An analysis of genes possibly regulated by miR-181a-2* was carried out and, amongst these, an inverse correlation of NAMPT with miR-181a-2* expression was observed, whereas, for TRAF1 and SALL1, additional regulation mechanisms involving CpG island methylation were observed. miR-181a-2* is associated with particular histological and molecular features of colorectal carcinomas within the serrated pathological pathway and might play a role in the immune responses of microsatellite instability carcinomas.
|
31784758 |
2019 |
|
Multiple Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
When TBS is used for therapeutic purposes, TBS protocols should be tailored according to the M1 plasticity functional reserve of each MS patient.
|
31715502 |
2019 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Effects of miR-4286 and SALL1 on PCa cell behaviors were examined in vitro.
|
31693770 |
2019 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Effects of miR-4286 and SALL1 on PCa cell behaviors were examined in vitro.
|
31693770 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Additionally, pre-clinical evaluation of SALL1 as a therapeutic target in AML is warranted.
|
29484122 |
2018 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
SALL1 functions as a tumor suppressor in breast cancer by regulating cancer cell senescence and metastasis through the NuRD complex.
|
29625565 |
2018 |
|
Parkinson Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Act5C: actin 5C; a.E.: after eclosion; Atg5: autophagy-related 5; Atg8a/LC3: autophagy-related 8a; CMA: chaperone-mediated autophagy; DHE: dihydroethidium; elav: embryonic lethal abnormal vision; eMI: endosomal microautophagy; ESCRT: endosomal sorting complexes required for transport; GABARAP: GABA typeA receptor-associated protein; Hsc70-4: heat shock protein cognate 4; HSPA8/Hsc70: heat shock protein family A (Hsp70) member 8; LAMP2: lysosomal associated membrane protein 2; MDA: malondialdehyde; PA-mCherry: photoactivable mCherry; PBS: phosphate-buffered saline; PCR: polymerase chain reaction; PD: Parkinson disease; Ref(2)P/p62: refractory to sigma P; ROS: reactive oxygen species; RpL32/rp49: ribosomal protein L32; RT-PCR: reverse transcription polymerase chain reaction; SING: startle-induced negative geotaxis; SNCA/α-synuclein: synuclein alpha; SQSTM1/p62: sequestosome 1; TBS: Tris-buffered saline; UAS: upstream activating sequence.
|
29989488 |
2018 |
|
Neoplasm, Residual
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Further studies to validate SALL1 as a potential biomarker for minimal residual disease (MRD) and to determine SALL1's role in prognostication are ongoing.
|
29484122 |
2018 |
|
Metabolic Syndrome X
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Components of metabolic syndrome and insulin resistance were associated with lower TBS in adults with T1D.
|
29290026 |
2018 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
SALL1 is a multi-zinc finger transcription factor that regulates organogenesis and stem cell development, but the role of SALL1 in tumor biology and tumorigenesis remains largely unknown.
|
29625565 |
2018 |
|
Leukemogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that SALL1 inhibition interrupts leukemogenesis.
|
29484122 |
2018 |
|
Basal-Like Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated that SALL1 functions as a tumor suppressor in breast cancer, which is significantly down-regulated in the basal like breast cancer and in estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) triple negative breast cancer patients.
|
29625565 |
2018 |
|
Middle Lobe Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Phenotypic and genotypic aspects of Townes-Brock syndrome: case report of patient in southern Brazil with a new SALL1 hotspot region nonsense mutation.
|
29110636 |
2017 |
|
Nephrosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Re-expression of Sall1 in podocytes protects against adriamycin-induced nephrosis.
|
28759006 |
2017 |
|
Nephrotic Syndrome
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Re-expression of Sall1 in podocytes protects against adriamycin-induced nephrosis.
|
28759006 |
2017 |
|
Glomerulosclerosis (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These protective aspects of Sall1 re-expression in injured podocytes may have the potential to reduce apoptosis and possibly glomerulosclerosis.
|
28759006 |
2017 |
|
Thalassemia Intermedia
|
0.010 |
Biomarker
|
disease |
BEFREE |
TBS values were significantly lower in TI patients than in 65 non-thalassemic controls (1.22 vs 1.36, p < 0.01), mainly in those splenectomized and in the transfused and chelated groups (p < 0.01).
|
28321531 |
2017 |
|
Vitelliform Macular Dystrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
TBS (Vex excluded) values decreased steadily with age with an overall loss of 8.99% between 52.5 and 77.5 years.
|
27900426 |
2017 |
|
Bilateral renal hypoplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Disruption of Sall1-NuRD <i>in vivo</i> in knock-in mice (Δ<i>SRM</i>) resulted in accelerated differentiation of nephron progenitors and bilateral renal hypoplasia.
|
28760814 |
2017 |
|
Nephrosis and Glomerulosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
To elucidate the role of Sall1 in injured podocytes, we used an adriamycin (ADR)-induced model of nephrosis and glomerulosclerosis.
|
28759006 |
2017 |
|
Becker Muscular Dystrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
TBS (Vex excluded) values decreased steadily with age with an overall loss of 8.99% between 52.5 and 77.5 years.
|
27900426 |
2017 |
|
Degenerative disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
The aim of this study was to measure changes in LS BMD and TBS in women 50 to 80 years old, taking into account the impact of fractured vertebrae and DD.
|
27900426 |
2017 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further survival analysis using the part of genes in the DMCN revealed high-risk group and low-risk group were distinguished by seven biomarkers (PCDHB15, WBSCR17, IGF1, GYPC, CYGB, ACTG2, and PRRT1) in breast cancer and eight biomarkers (ZBTB32, OR51B4, CCL8, TMEFF2, SALL3, GPSM1, MAGEA8, and SALL1) in colon cancer, respectively.
|
25774687 |
2015 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further survival analysis using the part of genes in the DMCN revealed high-risk group and low-risk group were distinguished by seven biomarkers (PCDHB15, WBSCR17, IGF1, GYPC, CYGB, ACTG2, and PRRT1) in breast cancer and eight biomarkers (ZBTB32, OR51B4, CCL8, TMEFF2, SALL3, GPSM1, MAGEA8, and SALL1) in colon cancer, respectively.
|
25774687 |
2015 |